Zepbound
- Active ingredient
- tirzepatide
- Class
- GIP and GLP-1 receptor agonist (dual agonist)
- Route
- Once-weekly subcutaneous injection
- Maker
- Eli Lilly
Educational only. This is educational, not medical advice. Everyone's body responds differently. Talk to your clinician before starting, stopping, changing, or tapering any medication, and work with your physician and a registered dietitian to personalize your approach.
Overview
Zepbound is the weight-management brand of tirzepatide, a dual agonist that activates both the GLP-1 and GIP receptors. The added GIP activity is thought to contribute to its strong appetite and metabolic effects.
It is the obesity-treatment counterpart to Mounjaro (the diabetes brand of the same molecule), and in head-to-head data tirzepatide has produced the largest average weight loss of the current GLP-1-class options.
Approval and use
| Approved for | Chronic weight management in adults with obesity or overweight with a weight-related condition (and obstructive sleep apnea in adults with obesity) |
| Weight use | On-label: Zepbound is approved specifically for weight management. |
Typical titration (informational)
Zepbound starts at a low weekly dose (commonly 2.5 mg) and steps up over months toward higher maintenance doses.
The target dose is individualized by the prescriber based on response and tolerance.
Background only; never adjust dosing yourself.
Expected timeline
In the SURMOUNT trials, tirzepatide produced average weight loss in the low-to-mid 20s percent of body weight at the highest dose over about 72 weeks, with the largest losses among the GLP-1 class.
Common side effects
- Nausea, particularly during escalation
- Diarrhea and constipation
- Vomiting
- Decreased appetite and fatigue
- Injection-site reactions
What happens when you stop Zepbound
Because tirzepatide drives larger losses on treatment, the rebound at cessation can also be larger in absolute terms. A withdrawal study of tirzepatide showed substantial regain after switching to placebo, mirroring the semaglutide pattern.
The mechanism is the same: appetite hormones rebound, food noise returns, and metabolic rate stays low. The off-ramp plan, protein, strength, sleep, and early tracking, is what blunts the slope.
Cost
Cash price has historically been around a thousand dollars a month; Lilly has offered lower-cost vial options and savings programs for some patients. Verify current pricing.
Frequently asked questions
Is Zepbound stronger than Wegovy?
In trials, tirzepatide (Zepbound) produced larger average weight loss than semaglutide (Wegovy), though individual response varies. Larger loss on treatment can mean a larger rebound if you stop without a maintenance plan.
Is Zepbound the same as Mounjaro?
Both are tirzepatide. Zepbound is the obesity brand; Mounjaro is the type 2 diabetes brand. Same molecule, different approved use.
Sources & further reading
Every claim on this page is drawn from peer-reviewed research, clinical trials, or recognized health authorities. Read the source before making any decision about your health.
- [1]Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regressionNIH/PMC
- [2]Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysisNIH/PMC
- [3]Resistance training as a key strategy for high-quality weight loss in men and womenNIH/PMC